PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).broad
PAH-Advance · Horizon Europe grant · 2023-01-01–2023-12-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
ATXA Therapeutics has developed NTP42, a disruptive new drug for pulmonary arterial hypertension (PAH) and related cardiopulmonary (heart & lung) diseases. NTP42 blocks the thromboxane receptor, a target at the root cause of PAH & related diseases. By treating all clinical hallmarks in both the LUNGS and HEART, NTP42 offers a game-changing solution for PAH leading to its rapid adoption once marketed. ATXAs Phase I clinical trial showed NTP42 is safe & highly efficacious in man.With EIC Blended Finance and VC co-investment, ATXA will undertake a Phase II trial on NTP42 in PAH. We will then secure a licensing deal with a pharma to ACCELERATE NTP42 to the PAH market (sales >$1B at 5 yrs post-launch & royalty returns to ATXA). With the proceeds of the licensing deal, we will DIVERSIFY uses of NTP42/pipeline drugs to treat other priority target diseases. This will also ENABLE growth (>100 FTEs), transforming ATXA into a major European pharma with a diversified diseases & drugs portfolio.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| ATXA THERAPEUTICS LTD | IE | coordinator | €2,500,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.